Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Phase 2

Conditions: Lung Adenocarcinoma

Interventions: Drug: Pemetrexed plus carboplatin combined with gefitinib
Drug: Gefitinib

First Posted Date: 2016-11-01

Last Posted Date: 2016-11-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 300

Registration Number: NCT02951637

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Phase 2

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: pemetrexed or gemcitabine plus carboplatin,
Drug: bevacizumab

First Posted Date: 2016-10-12

Last Posted Date: 2016-10-13

Lead Sponsor: Caicun Zhou

Target Recruit Count: 180

Registration Number: NCT02930954

Locations: 🇨🇳
Department of Oncology, Shanghai pulmonary hospital, Shanghai, China

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Phase 3

Conditions: Cancer

Interventions: Drug: gefitinib
Drug: Yiqi-yangyin-jiedu decoction
Drug: placebo

First Posted Date: 2016-10-11

Last Posted Date: 2019-04-11

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 198

Registration Number: NCT02929693

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

Phase 2

Active, not recruiting

Conditions: NSCLC

Interventions: Drug: Osimertinib
Drug: Gefitinib

First Posted Date: 2016-08-05

Last Posted Date: 2022-09-15

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 156

Registration Number: NCT02856893

Locations: 🇫🇷
CHU de Brest, Brest, France
🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇫🇷
Institut Paoli-Calmettes, Marseille, France

and more 19 locations

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2

Conditions: Gallbladder Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct

Interventions: Procedure: biological test
Drug: GEMOX
Drug: Cetuximab
Drug: Trastuzumab
Drug: Gefitinib
Drug: Lapatinib
Drug: Everolimus
Drug: Sorafenib
Drug: Crizotinib

First Posted Date: 2016-07-19

Last Posted Date: 2018-05-07

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 152

Registration Number: NCT02836847

Locations: 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Phase 3

Conditions: EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

Interventions: Drug: Apatinib
Drug: Placebo
Drug: Gefitinib

First Posted Date: 2016-07-06

Last Posted Date: 2016-07-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 246

Registration Number: NCT02824458

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2016-06-17

Last Posted Date: 2021-06-02

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 15

Registration Number: NCT02804776

Locations: 🇸🇬
National Cancer Centre, Singapore, Singapore

Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Completed

Conditions: Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?

Interventions: Drug: Gefitinib

First Posted Date: 2016-04-15

Last Posted Date: 2016-04-15

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 100

Registration Number: NCT02740894

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Phase 3

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: naquotinib mesilate
Drug: Erlotinib
Drug: Gefitinib

First Posted Date: 2015-10-27

Last Posted Date: 2024-12-10

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 530

Registration Number: NCT02588261

Locations: 🇺🇸
Site US10025, Fountain Valley, California, United States
🇺🇸
Site US10003, Santa Monica, California, United States
🇺🇸
Site US10013, Aventura, Florida, United States

and more 164 locations

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Phase 3

Conditions: Lung Neoplasms

Interventions: Drug: Gefitinib
Drug: Pemetrexed

First Posted Date: 2015-08-10

Last Posted Date: 2015-08-10

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 220

Registration Number: NCT02518802

Locations: 🇨🇳
Tangdu Hospital of the Fourth Millitary Medical University, Xi'an, Shaanxi, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy